Thorsten Waloschek: Addressing Risks in Pregnancies with Sclerosis
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“A new study from The Lancet Rheumatology caught my attention this week.
It examines pregnancy outcomes in women with systemic sclerosis and highlights a reality we still need to confront. Even with a high live birth rate, the risks for mothers remain significantly elevated, particularly when it comes to preeclampsia, placental insufficiency, preterm birth, and severe postpartum complications.
Pregnancy places an extraordinary cardiovascular demand on the body, and for women with underlying autoimmune or vascular conditions, those risks can rise sharply. What concerns me most is that nearly 40 percent of pregnancies in the study showed worsening disease during pregnancy or within the first year postpartum. It reinforces something many in maternal health already know: we still lack effective, accessible tools for early risk detection.”
Read more.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Aug 3, 2026, 14:19Asmaa Khaled: The Success of IVF is Not Determined By the Number of Eggs Retrieved Alone…
-
Aug 3, 2026, 14:03Clare Mansfield: Sometimes the Path to Parenthood Changes, but the Dream Doesn’t Have To
-
Aug 3, 2026, 13:45Undiga Emuekpere: Basic Fertility Health Awareness Could Change Outcomes
-
Aug 3, 2026, 13:31Priyadatt Patel: A Quiet Inefficiency in How We Approach Infertility Deserves More Attention
-
Aug 3, 2026, 13:21Purabi Gunjal: Most Women Start Thinking about Fertility Too Late…
-
Aug 3, 2026, 13:10Juhee Jain: Empowering Women with the Right Information to Make Informed Decisions
-
Aug 3, 2026, 12:57Ashley Evans: Sometimes, the Thing that Got Me Through Fertility Treatment Wasn’t Positivity…
-
Aug 3, 2026, 12:42Devyanshi Dixit: Why Do the Best Healthcare Professionals Never Stop Learning?
-
Aug 3, 2026, 12:30Bringing Together the Brightest Minds in Reproductive Medicine for 3 Days at MEFS 2026
